Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flortaucipir F 18 Phase 2 Imaging Study in Nervous System Diseases (France)
2019-002694-63Phase 2Active
- Sponsor
- Inserm
- Start
- Sep 2019
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of flortaucipir in neurological diseases, sponsored by Inserm. Started Sep 2019; status: active.
02
Drugs
flortaucipir
03
Conditions
neurological diseases
Beyond the preview
Go deeper on 2019-002694-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002694-63.